Table 1

Patient characteristics

All patients

n = 134


Mean age at diagnosis; years (SD) (range)

63.2 (8.3) (47-80)


Mean follow-up time; years (SD)

10.1 (3.5)


RF positive (%)

94/132 (71.2)


Anti-CCP positive (%)

34/57 (59.6)


Smoking at diagnosis (%)

39/118 (33.1)


Low formal education (< 8 years of school) (%)

66/128 (49.3)


Prednisolone at diagnosis (%)

39/120 (32.5)


Biological treatment ever (%)

37/133 (27.8)


Number of used DMARDS; median (IQR)

2 (1-3)


> 3 DMARDs used (%)

30 (22.4)


DMARDS in combination (%)

54 (40.3)


Documented radiographic erosions (ever) (%)

71/125 (56.8)


Severe extraarticular manifestations (%)

7 (5.2)


Median HAQ at diagnosisa

0.87


Median HAQ 1 year after diagnosisa

0.75


Median HAQ 5 years after diagnosisa

0.75


Median HAQ 10 years after diagnosisa

0.88


CCP, cyclic citrullinated peptide; DMARD, disease-modifying antirheumatic drug; HAQ, Health Assessment Questionnaire; IQR, interquartile range; RF, rheumatoid factor; SD, standard deviation. aData available for HAQ at diagnosis in 70 cases, for HAQ at 1 year in 82 cases, for HAQ at 5 years in 92 cases, and for HAQ at 10 years in 63 cases.

Pikwer et al. Arthritis Research & Therapy 2012 14:R190   doi:10.1186/ar4021

Open Data